Risk prediction in mds: independent validation of the ipss-m⠎ready for routine?

HIGHLIGHTS

• who: Constance Baer from the University of Leipzig, Germany have published the research: Risk prediction in MDS: independent validation of the IPSS-Mu280eready for routine?, in the Journal: (JOURNAL) of 17/01/2023
• what: While all new molecular risk prediction tools for MDS have been shown to be superior to the IPSS-R , the objective of the given tool should be tailored to the application (e_g, personal therapeutic decision making or clinical study design).
• how: The authors identified NPM1 mutations which are also integrated into the IPSS-M model in 4 cases (1 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.